A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

3,146

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

June 30, 2015

Conditions
Cholera
Interventions
BIOLOGICAL

PXVX0200 Lot A

Lot P700-1CA03

BIOLOGICAL

PXVX0200 Lot B

Lot P700-3CA03

BIOLOGICAL

PXVX0200 Lot C

Lot P700-6BA03

BIOLOGICAL

Placebo

Placebo

Trial Locations (25)

3004

Nucleus Network, Melbourne

3145

Emeritis Research, Malvern East

4006

QIMR Berghofer Medical Research Institiue, Herston

4035

AUS Trials Pty Ltd, Sherwood

5000

CMAX, Adelaide

6009

Linear Clinical Research, Nedlands

14609

Rochester Clinical Research, Rochester

29464

Coastal Carolina Research, Mt. Pleasant

30322

Emory University, Atlanta

32720

Avail Clinical Research, DeLand

33143

Miami Research Associates, Miami

33409

Palm Beach Research, West Palm Beach

36608

Coastal Clinical Research, Mobile

40509

Central Kentucky Research, Lexington

40536

University of Kentucky, Lexington

63104

St. Louis University, St Louis

64114

Center for Pharmaceutical Research, Kansas City

66219

Johnson County Clin-Trials, Lenexa

67207

Heartland Research Associates, Wichita

73069

Lion Research, Norman

75234

Research Across America, Dallas

84124

Jean Brown Research, Salt Lake City

85004

Clinical Reseach Consortium Arizona, Phoenix

89119

Clinical Research Consortium Las Vegas, Las Vegas

02218

Boston University, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Emergent BioSolutions

INDUSTRY

lead

Bavarian Nordic

INDUSTRY